Back to results
US 2020/0339469 A1Published application
Pharmaceutical glass coating for achieving particle reduction
AssigneeCorning Incorporated
InventorsJohn Frederick Bayne, Dana Craig Bookbinder, Theresa Chang, Steven Edward DeMartino, Andrei Gennadyevich Fadeev, Kyle Christopher Hoff, Jamie Lynne Morley, Santona Pal, John Stephen Peanasky, Chandan Kumar Saha, Christopher Lee Timmons
Life of this patent
Estimating the term…
Abstract
Embodiments of the present disclosure are directed to coated glass articles which reduce glass particle formation caused by glass to glass contact in pharmaceutical glass filling lines.
Claims22
A coated glass article comprising:
- a glass body formed from an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard or a borosilicate glass that meets the Type 1 criteria according to USP <660>, the glass body having a first surface and a second surface opposite the first surface, wherein the first surface is an exterior surface of the glass body;
- and
- a coating disposed on at least a portion of the exterior surface of the glass body, the coating comprising a polymer, wherein the coated glass article reduces particle generation when the coated glass article undergoes processing,
- wherein the coated glass article demonstrates at least a 50% reduction in average particle count for generated glass particles compared to an average particle count of generated glass particles by an uncoated glass article that undergoes the processing, wherein the average glass particle count is computed for glass particles equal to or greater than 10 μm and glass particles equal to or greater than 25 μm using light obscuration according to United States Pharmacopoeia Standard 788 and the % reduction is determined for the sum of the average glass particle count for glass particles equal to or greater than 10 μm and the average glass particle count for glass particles equal to or greater than 25 μm.
1 more element
A coated glass article comprising:
- a glass body formed from an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard or a borosilicate glass that meets the Type 1 criteria according to USP <660>, the glass body having a first surface and a second surface opposite the first surface, wherein the first surface is an exterior surface of the glass body;
- and
- a coating disposed on at least a portion of the exterior surface of the glass body, the coating comprising a polymer, wherein:
- the coated glass article reduces glass particle formation caused by non-breakage inducing glass contact in pharmaceutical glass filling lines, the reduction in glass particle formation being defined as follows:
- wherein an average particle count of generated sub-visible glass particles having a size of equal to or greater than 10 μm and equal to or greater than 25 μm is below allowable levels defined by United States Pharmacopoeia Reference Standard 788, the average particle count being computed using light obscuration;
- and
- wherein the coated glass article demonstrates at least a 50% reduction in average glass particle count for generated glass particles compared to an average glass particle count of generated glass particles by an uncoated glass article in the pharmaceutical glass filling lines, wherein the average glass particle count is computed for glass particles equal to or greater than 10 μm and glass particles equal to or greater than 25 μm using light obscuration according to United States Pharmacopoeia Standard 788 and the % reduction is determined for the sum of the average glass particle count for glass particles equal to or greater than 10 μm and the average glass particle count for glass particles equal to or greater than 25 μm.
4 more elements
Dependencies are inferred from the claim text.